Ocugen

This study tests a gene therapy called OCU410ST for people with Stargardt disease, an inherited eye condition that causes vision loss. The trial includes 51 participants, some receiving the treatment and others serving as an untreated control group. Early results suggest the ther…

This study tests a new gene therapy called OCU410 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The trial involves up to 60 participants aged 50 and older and aims to check the treatment's safety and whether …

This program offers up to 75 adults with retinitis pigmentosa access to an experimental treatment called OCU400. It is for people who cannot join the main Phase 3 study and have no other FDA-approved options. The goal is to provide treatment while gathering more safety and effect…

This study tests a gene therapy called OCU400 for people with retinitis pigmentosa, an eye disease that causes vision loss. The treatment is injected under the retina to help slow or improve vision. The trial enrolled 140 people aged 3 and older and measures how well they can nav…